Clinical Trial Update: Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating durvalumab and tremelimumab in recurrent stage IV squamous cell lung carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Squamous Cell Carcinoma of the Lung
• Squamous Cell Lung Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2022-01-21